Droplex PIK3CA Mutation Test
Detection of the 11 defined mutations within the catalytic a-subunit of the PI3K gene
Features
Breast Cancer (BC) is the most common cancer in women and is the second leading cause of death in Women. ER+ and HER2- type tumor accounts for about 71 % of all Breast cancer patients, and 40 % of those BC patients have PIK3CA mutations. When a patient has a PIK3CA mutation, they are likely to be resistant to chemotherapy. Therefore, knowing the existence of PIK3CA mutation is important in treating breast cancer patients with appropriate drugs. The CE-IVD certified Droplex PIK3CA Mutation Test detects 11 defined mutations within the catalytic a-subunit of the PI3K gene using Digital DropletTM Technology as a companion diagnostic.
BIOTYPE is the exclusive distributor of the PIK3CA Droplex Test in Germany and Austria. The legal manufacturer of the kits is GENCURIX, Inc.
Biomarkers
Exon 7: C420R
Exon 9: E542K, E545K/A/G/D, Q546E/R
Exon 20: H1047R/L/Y
Product specifications
- Cat No.
- CD006
- Cancer type
- Breast Cancer
- Regulatory status
- CE-IVD
- Compatible sample type
- DNA from FFPE tissue, cfDNA from Plasma
- Mutation variants
- 11
- Kit size/reactions
- 24 samples/kit (4 well-reactions/sample)
- Platform
- Digital DropletTM PCR
Resources
Ordering Information
Droplex PIK3CA Mutation Test
Kit size/reactions: 24 samples/kit (4 well-reactions/sample)
Cat.No.: CD006
Status: CE-IVD
Product Request
MODAPLEX
Bench-top system for molecular multi-marker testing
